TriSalus Life Sciences In... (TLSIW)
NasdaqGM: TLSIW
· Real-Time Price · USD
1.25
+0.05 (4.17%)
At close: Aug 12, 2026, 3:34 PM
TriSalus Life Sciences Inc. (TLSIW) Stock Price, Analysis & Data
4.17% (1D)
| Bid | n/a |
| Market Cap | n/a |
| Revenue (ttm) | 45.08M |
| Net Income (ttm) | -57.25M |
| Beta | 0.43 |
| EPS (ttm) | n/a |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| P/B (ttm) | 5.98 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | n/a |
| Volume | 2,708 |
| Avg. Volume (20D) | 4,879 |
| Open | 1.11 |
| Previous Close | 1.20 |
| Day's Range | 1.20 - 1.25 |
| 52-Week Range | 0.44 - 2.29 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About TLSIW
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures...
IPO Date Feb 9, 2021
Employees 102
Stock Exchange NasdaqGM
Ticker Symbol TLSIW
Website https://trisaluslifesci.com
Financial Performance
In 2025, TriSalus Life Sciences's revenue was 45.15M, an increase of 53.41% compared to the previous year's 29.43M. Earnings were -39.23M, an increase of 30.56%.
Financial Statements
Page 1 of 2